Replies to post #188209 on Biotech Values

[caravon]

willyw,

Did you attend the last Enta's AM?

If you did, you remember that Luly has spent at least 30 minutes explaining the specificity and Enta general drug development philosophy for HCV.

Luly also explained why Gild selected to buy Pharmasset for $11B instead of developing their own HCV candidates at that time.

Regards, caravon